Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis

Conner E. Johnson,Whitney B. Sussman,Erin R. Weeda

DOI: https://doi.org/10.1111/dom.15809

2024-07-25

Diabetes Obesity and Metabolism

Abstract:Aim To perform a meta‐analysis comparing real‐world medication adherence to sodium–glucose cotransporter‐2 inhibitors (SGLT2is) versus glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). Materials and Methods A systematic search of Medline and Embase was conducted through October 2023. To meet inclusion criteria, articles had to be published in full text form and directly compare medication adherence to SGLT2is versus GLP‐1RAs in adults. Only studies evaluating real‐world data and utilizing the proportion of days covered (PDC) to measure adherence were included. Non‐adherence, defined as the proportion of patients with a PDC <80%, was the primary outcome. A subgroup analysis evaluating results among studies conducted in the United States was performed. Results We identified eight studies evaluating 205 103 patients for inclusion. The most common country from which the data was derived was the United States (n = 5 studies). Upon meta‐analysis, we observed no difference in non‐adherence (i.e. PDC <80%) to SGLT2is versus GLP‐1RAs (relative risk = 0.86; 95% confidence interval = 0.72–1.02). In the analysis, including only US studies, SGLT2i use was associated with a 23% lower risk of non‐adherence compared with GLP‐1RA use (relative risk = 0.77; 95% confidence interval = 0.72–0.82). Conclusions In this meta‐analysis of eight studies that included approximately 200 000 patients, there was no difference in adherence to SGLT2is versus GLP‐1RAs. However, SGLT2i use was associated with higher adherence when the analysis was limited to US studies.

endocrinology & metabolism